Ultomiris Safe and Effective for Children With aHUS, Phase 3 Trial Shows

Ultomiris Safe and Effective for Children With aHUS, Phase 3 Trial Shows

287860

Ultomiris Safe and Effective for Children With aHUS, Phase 3 Trial Shows

Ultomiris (ravulizumab-cwvz) is safe and effective in children with atypical hemolytic uremic syndrome (aHUS), data from a Phase 3 clinical trial show. These findings were in the study “The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment,” published in Kidney International. aHUS is caused by abnormal activation of part of the immune system called the complement system, resulting in the progressive destruction of red blood…

You must be logged in to read/download the full post.